Navigation Links
Research Shows Way for Drug Therapy for Autism

Indian neuroscientists are part of an international team that has for the first time reversed symptoms of mental retardation and autism in mice, raising hopes of drug therapy for this disorder that affects one in 500 children.

Researchers at the National Centre for Biological Sciences (NCBS) and National Institute of Mental Health and Neuroscience (NIMHANS) in Bangalore have contributed to the breakthrough, reported this week's Proceedings of the National Academy of Sciences (US).

Scientists at the Massachusetts Institute of Technology (MIT) in the US and Seoul National University in South Korea are part of the team.

Autism is a developmental disorder characterised by varying degrees of deficiencies in communication skills and social interactions, along with restricted, repetitive and stereotyped patterns of behaviour.

A strain of mice, genetically engineered by the Nobel laureate Susumu Tonegawa and colleagues at MIT, were manipulated to model "fragile X syndrome (FXS)", the leading inherited cause of mental retardation and the most common genetic cause of autism.

"The condition, tied to a mutated gene in the X chromosome, causes mild learning disabilities to severe autism," researcher Sumantra Chatterji at NCBS told IANS. Presently, there is no effective treatment for FXS and other types of autism affecting all races and ethnic groups, he said.

"Our findings have identified a specific enzyme in the brain, called p21-activated kinase (PAK), as a potential target for drugs that may reverse many of the debilitating symptoms of FXS, and possibly autism, in children.

"The enzyme PAK affects the number, size and shape of connections between neurons in the brain," he said.

In the brain, these connections between neurons are formed by small protrusions called "spines", which are spread on branches of neurons called "dendrites". The numbers and shapes of dendrit ic spines are crucial for normal brain function.

FXS patients have higher numbers of dendritic spines in their brains, but each spine is longer and thinner than in normal individuals.

"Our analysis shows that inhibition of PAK activity reverses the structural abnormality of neuronal connections seen in FXS mice," said Shankaranarayana Rao of NIMHANS, who was part of the study.

In addition to structural problems, these abnormal connections between neurons transmit weaker electric signals in FXS mice.

"Strikingly, blocking PAK activity also helped restore electrical signalling between neurons in the brains of the FXS mice," Chatterji said.

Interestingly, the FXS mice also exhibit abnormal behavioural symptoms like hyperactivity, purposeless, repetitive movements and learning difficulties commonly seen in autistic patients.

These behavioural problems are also ameliorated in the FXS mice with reduced PAK activity, the Indian researchers said.

Chatterji pointed out that the cutting-edge genetic engineering techniques used by his collaborators at MIT created a unique situation where PAK activity was blocked only after the debilitating symptoms of FXS had already taken hold in the mice.

"That PAK inhibition can reverse pre-existing symptoms of FXS is very good news for future design of drugs for treating fragile X in kids," said Chatterji.

There are known chemical compounds that inhibit the activity of PAK. These compounds or new ones targeted at PAK may greatly facilitate future development of drugs against FXS, and possibly autism as well, he said.


'"/>




Related medicine news :

1. Kidney Stones - Interesting New Research implicates bacteria as its cause
2. Researchers urge caution in using ear tube surgery
3. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
4. Researchers Scale to assess the Severity of Epilepsy in Kids
5. Research of Ritalin
6. Researchers trick Alzheimers Enzyme
7. Researchers find new HIV hiding place
8. A Compilation of recent Diabetes Research articles
9. Research on causes for falling helps develop preventive strategies
10. New standards for Human Research Safety
11. Research on Celiac Disease in children
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will ... Diego honoring the 2016 MPN Heroes—eight individuals who have made a difference in the ... beyond the standard of care, demonstrating leadership within the MPN community and/or a commitment ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than 100 business, civic, ... to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, 2016. This inaugural event, ... and operating support to UNCF-member institutions, including Miles College, Oakwood University, Tuskegee University, ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... launch of its 60-day free trial program for all of the company’s desktop ... offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use an ...
(Date:12/2/2016)... ... 2016 , ... The annual time frame to change Medicare health and prescription ... December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan ... to make changes during this period order for their new policy to go into ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain ... an injury, patients must find the one that works for them. When an inventor ... a machine that worked and decided to share it with others. , He developed ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... British Columbia , December 2, 2016 bioLytical ... bekannt gegeben, ab diesem Monat seinen  INSTI HIV-Selbsttests  in einer Version mit ... ... New: INSTI Self Test! ... , ,      (Photo: ...
(Date:12/2/2016)... The iShares Nasdaq Biotechnology Exchange-Traded Fund ... victory early in November. Less political risk has boosted ... predicting an uptick in M&A activities. Today, Stock-Callers.com takes ... they have fared at the last close: Celldex Therapeutics ... (NASDAQ: FOLD ), Navidea Biopharmaceuticals Inc. (NYSE ...
(Date:11/30/2016)... Nov 30, 2016 Research and ... Overview for Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices 2017 - ... ... The full report suite on the U.S. market ... drainage systems, intracranial pressure monitoring devices, detachable coils, liquid embolics, ...
Breaking Medicine Technology: